Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HaemoCer is a plant-based, absorbable polysaccharide hemostatic powder used as an adjunct to control bleeding during surgical procedures. It contains no animal or human components and is manufactured using BioCer's proprietary Polysaccharide Ultra-hydrophilic Resorbable Engineering (PURE) process. Upon contact with blood, HaemoCer rapidly dehydrates the blood at the application site, concentrating platelets, red blood cells, and coagulation proteins to enhance the natural clotting cascade. It also forms a gelled matrix that adheres to tissue and acts as a mechanical barrier to further bleeding. The product is fully resorbed by amylase within days after application without leaving residues. Indications include use in general surgery for capillary, venous, or arteriolar bleeding when conventional methods are ineffective or impractical; it can also serve as an adhesion prevention barrier in both open and minimally invasive procedures[1][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Haemocer.